Internal Medicine, Hematology & Oncology · Roseville, CA
NPI
1548242308
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-5626
Groups this clinician bills Medicare through
Medicare paid, 2024
$36K
1,629 services
Medicare patients, 2024
16
Average age 60
Drug cost, 2024
$10.3M
2,881 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Lisa Law prescribed most often to Medicare patients was Brukinsa (Zanubrutinib), with 251 prescriptions and refills. In total Lisa Law wrote 2,881 Medicare prescriptions that cost $10.3M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-28.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Brukinsa Zanubrutinib | 251 | 253 | 35 | $3.0M |
| Acyclovir Generic | 241 | 498 | 75 | $5,723 |
| Lenalidomide Generic | 211 | 211 | 31 | $2.7M |
| Hydroxyurea Generic | 117 | 296 | 33 | $4,682 |
| Allopurinol Generic | 112 | 196 | 52 | $958 |
| Prochlorperazine Maleate Generic | 110 | 110 | 70 | $1,591 |
| Prednisone Generic | 106 | 159 | 56 | $1,328 |
| Nivestym Filgrastim-Aafi | 97 | 97 | 32 | $94K |
| Dexamethasone Generic | 94 | 178 | 43 | $2,652 |
| Posaconazole Generic | 67 | 67 | 14 | $13K |
| Ondansetron Hcl Generic | 65 | 66 | 34 | $587 |
| Jakafi Ruxolitinib Phosphate | 65 | 65 | Under 11 | $621K |
| Atovaquone Generic | 63 | 63 | 21 | $21K |
| Entecavir Generic | 60 | 146 | 20 | $1,660 |
| Famotidine Generic | 59 | 161 | 36 | $690 |
Brand drugs: 818 claims; generic drugs: 2,063 claims; opioid claims: 164.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Lisa Law were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.